XML 70 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration and Other Agreements - Zai Lab (Details) - USD ($)
$ in Thousands
1 Months Ended 2 Months Ended 12 Months Ended
Jun. 30, 2021
Nov. 30, 2018
Feb. 24, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jun. 15, 2021
Feb. 29, 2020
Collaboration and Other Agreements [Line Items]                
Revenues       $ 77,447 $ 104,883 $ 64,188    
Zai Lab Agreement | Zai Lab                
Collaboration and Other Agreements [Line Items]                
Non-refundable upfront payment   $ 25,000            
Tax withholding   $ 2,500            
Potential development and regulatory milestone payments       140,000        
Entitled milestone payments               $ 3,600
Zai Lab Agreement, Margetuximab | Zai Lab | Maximum                
Collaboration and Other Agreements [Line Items]                
Potential proceeds from royalties percent   20.00%            
Zai Lab Agreement, TRIDENT molecule | Zai Lab                
Collaboration and Other Agreements [Line Items]                
Potential proceeds from royalties percent   10.00%            
Zai Lab Clinical Supply Agreements | Zai Lab                
Collaboration and Other Agreements [Line Items]                
Revenues       2,800 2,700      
Zai Lab Collaboration And License Agreement | Zai Lab                
Collaboration and Other Agreements [Line Items]                
Non-refundable upfront payment, net of tax withholding   $ 22,500            
Revenues         4,000      
Revenues, tax withholding         400      
Zai Lab Collaboration And License Agreement | Zai Lab | Subsequent Event                
Collaboration and Other Agreements [Line Items]                
Revenues     $ 5,000          
2018 Zai Lab Collaboration And License Agreement | Zai Lab                
Collaboration and Other Agreements [Line Items]                
Revenues, Net Of Tax Withholding         $ 8,600      
Deferred revenue       0        
2021 Zai Lab Agreements | Zai Lab                
Collaboration and Other Agreements [Line Items]                
Non-refundable upfront payment $ 25,000              
Potential development and regulatory milestone payments             $ 800,000  
Revenues       20,300        
Deferred revenue       16,100        
Estimated Reimbursement for Research and Development t       $ 5,000        
Opt-in Fee             85,000  
Potential commercial milestone payments             600,000  
Transaction price             $ 40,400  
2021 Zai Lab Agreements | Zai Lab | Additional Paid-In Capital                
Collaboration and Other Agreements [Line Items]                
Premium received on stock purchase $ 10,400